{"version":"1.0","type":"rich","provider_name":"Acast","provider_url":"https://acast.com","height":250,"width":700,"html":"<iframe src=\"https://embed.acast.com/$/67105af848726944170ab1fe/673eeb9ffc7e86ea70ede34f?\" frameBorder=\"0\" width=\"700\" height=\"250\"></iframe>","title":"Michael Severino: Towards In Vivo Genome Editing of Humans","description":"<p>Michael Severino, MD,&nbsp;discusses the approaches for developing \"genome writers\" at Tessera Therapeutics, where he joined as CEO in 2022, and the advantages of performing <em>in vivo </em>genome editing over <em>ex vivo</em> approaches. Severino explains where the company is in utilizing its genome writing platform to perform edits <em>in vivo</em> on its journey toward the clinic.</p><p><br></p><p><em>Stay up to date with the latest episodes of Behind the Breakthroughs by subscribing to the IPM eNewsletter&nbsp;</em><a href=\"https://www.insideprecisionmedicine.com/newsletter-sign-up/\" rel=\"noopener noreferrer\" target=\"_blank\"><em>here</em></a><em>.</em></p><p><br></p><p><em>Produced by Bill Levine</em></p><p><em>Hosted by Jonathan D. Grinstein, PhD</em></p><p><em>Music provided by Artem Hramushkin</em></p><p><em>Audio mixed and mastered by Jason Mack</em></p><p><br></p>","author_name":"Inside Precision Medicine"}